TITLE:
Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2

CONDITION:
Non-Small Cell Lung Cancer

INTERVENTION:
Tarceva (Trademark) (erlotinib HCl, OSI-774)

SUMMARY:

      The purpose of this noncomparative study is to obtain preliminary estimates of the efficacy
      of erlotinib and standard chemotherapy in patients with advanced, previously untreated
      nonsmall cell lung cancer (NSCLC) and an Eastern Cooperative Oncology Group (ECOG)
      performance status (PS) of 2. The study will also evaluate the safety of single-agent
      erlotinib in this patient population.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria:

          -  Stage IIIB or IV Nonsmall cell lung cancer (NSCLC)

          -  No prior chemotherapy

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status 2

          -  Clinically or radiologically measurable disease per RECIST criteria

        Exclusion Criteria:

          -  Gastro-intestinal abnormalities

          -  Any concurrent anticancer therapy

          -  Prior treatment with epidermal growth factor receptor (EGFR) inhibitors of any kind

          -  Other active malignancies

          -  Uncontrolled brain metastases

          -  Severe abnormalities of the cornea

          -  Significant cardiac disease
      
